Drug tolerability, defined as the level of patient acceptance of adverse effects such as nausea, dry mouth, headache, diarrhea/constipation or mood change,  has a significant impact on quality of life and treatment adherence. Addressing tolerability issue in the early phase of drug discovery  is the cornerstone of Giiant’s research strategy. With the specific aim of bringing to patients a new therapeutic option for the treatment of IBD, Giiant Pharma has developed a gut-specific delivery platform. By targeting one single organ, improved tolerability arises from the lack of systemic exposure while sustained efficacy is ensured by the higher mucosal drug concentration at the site of inflammation.